Results of a phase II clinical trial conducted at MD Anderson Cancer Center revealed combination targeted therapy, consisting of rituximab, lenalidomide, and ibrutinib, had an 84.6% overall response rate and 38.5% complete response rate when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large B-cell lymphoma.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
